The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.25
Bid: 19.00
Ask: 19.50
Change: -0.25 (-1.28%)
Spread: 0.50 (2.632%)
Open: 19.50
High: 19.50
Low: 18.50
Prev. Close: 19.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio Company Announces Strengthening Sales

24 Oct 2011 07:00

RNS Number : 6687Q
Angle PLC
24 October 2011
 



For immediate release

24 October 2011

 

ANGLE plc

 

("ANGLE" or the "Company")

 

PORTFOLIO COMPANY GEOMERICS ANNOUNCES STRENGTHENING SALES

 

 

ANGLE plc, which focuses on the commercialisation of technology, is pleased to announce that its 33% owned portfolio company Geomerics, which specialises in computer games middleware, has made significant progress on a number of fronts.

 

Sales continue to grow at an encouraging rate. Geomerics' Enlighten technology is now being employed in 18 titles worldwide and is currently in evaluation and under consideration for many more. Among these titles are two of the most hotly anticipated games of 2011. Battlefield 3, from EA DICE, is released on 28th October. It is considered a challenger to Call of Duty's market dominance. The game has been backed by a $100m marketing campaign and has received high praise and multiple awards for the quality of its graphics, of which the lighting is driven by Geomerics' Enlighten engine. Battlefield 3 is followed by the release of Need for Speed: The Run on 18th November. This is the next game in one of the most successful franchises of all time and is built on the same Enlighten technology as Battlefield 3.

 

Geomerics is also delighted that it has secured its first deal inside Korea, which will see Enlighten used in multiple titles. This opens up a whole new market for Enlighten and, on the back of sales in Japan, demonstrates that Geomerics is on its way to establishing a strong base in the Asian market.

 

Geomerics' participation in Epic Games' prestigious Unreal Engine 3 Integrated Partners Programme continues to go well and is yielding a range of new sales opportunities.

 

Finally, Geomerics has been awarded new grant funding to research applications of its technology on mobile devices. Geomerics will receive €470,000 over the next three years as part of a €2.8 million EU-funded project researching the next generation of graphics technology for mobile platforms.

 

 

 

Chris Doran, Founder of Geomerics, commented:

"At Geomerics we have tracked the rise in performance of mobile platforms very closely. It is clear that they are fast approaching console performance, and at the high end will overtake this in 2012. We are very excited about the prospect of taking our console technology to mobile platforms, and to contributing to joint R&D on the future direction of graphics technology for mobile devices."

 

 

Andrew Newland, Chief Executive of ANGLE commented:

"We are very pleased with the Geomerics' continued strong progress and look forward to the positive market impact when Battlefield 3 launches at the end of this week."

 

 

 

 

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Collins Stewart Europe Limited

Matt Goode

 

0207 523 8325

Buchanan

Lisa Baderoon

 

0207 466 5000

Scott Harris

Stephen Scott, Harry Dee

 

0207 653 0030

 

 

About Geomerics www.geomerics.com

 

Geomerics is an innovation-led company developing cutting-edge graphics technology for the games industry. Based in Cambridge, UK, Geomerics has built a team that combines world-class management and games industry experience with some of the UK's leading researchers. Geomerics launched its groundbreaking Enlighten technology in 2009. Enlighten redefines how designers use and control lighting within a game.

 

Geomerics partners with many of the leading companies in the games industry and is currently working with developers around the world on AAA titles for release in 2011 and 2012. The first titles incorporating Enlighten include the highly anticipated 'Battlefield 3' and 'Need for Speed: The Run'.

 

For more details about Geomerics research into mobile platforms, visit www.lpgpu.org 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBRBDGLBDBGBX
Date   Source Headline
6th Jul 201710:05 amRNSNotice of Results
4th Jul 20177:00 amRNSSuccessful Headline Data in Ovarian Cancer Studies
15th Jun 20177:00 amRNSParsortix breakthrough in prostate cancer
5th Jun 20177:00 amRNSSuccess with Parsortix in Colorectal Cancer
3rd May 20177:00 amRNSBusiness Update
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSParsortix enables analysis in head and neck cancer
30th Mar 20177:00 amRNSProstate Cancer Update
14th Feb 201711:39 amEQSEdison issues outlook on Angle
13th Feb 20177:00 amRNSSelected for European Cancer ID Programme
26th Jan 20177:01 amRNSInterim Evaluation of Ovarian Cancer Study
26th Jan 20177:00 amRNSInterim Results
4th Jan 20177:00 amRNSNotice of Results
28th Nov 20167:00 amRNSISSUE OF SHARE OPTIONS
24th Nov 20162:48 pmRNSResult of GM
4th Nov 20167:00 amRNSBarts Research Supports Potential Use of Parsortix
1st Nov 20167:00 amRNSNotice of GM
27th Oct 20167:00 amRNSDirector's share purchase
7th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20164:35 pmRNSResult of AGM
30th Sep 20167:00 amRNSResearch published in Clinical Chemistry
19th Sep 201611:14 amRNSIssue of Equity
9th Sep 20164:12 pmRNSAnnual Report and Accounts and Notice of AGM
4th Aug 20167:00 amRNSMD Anderson Cancer Center poster presentation
2nd Aug 20163:37 pmRNSEdison issues ADR update on Angle
28th Jul 20167:00 amRNSUse of Parsortix in GANNET53 drug trial
28th Jul 20167:00 amRNSPreliminary Results
27th Jul 20167:00 amRNSInitiation of 200 patient US ovarian cancer study
19th Jul 20167:00 amRNSInitiation of European ovarian cancer study
15th Jul 20167:00 amRNSNotice of Results
15th Jul 20167:00 amRNSParsortix gaining traction at EACR Conference
1st Jun 20163:04 pmRNSHolding(s) in Company
31st May 20164:36 pmRNSHolding(s) in Company
27th May 20163:12 pmRNSEdison issues research update on Angle
25th May 20167:00 amRNSCancer Research UK Contract
25th May 20167:00 amRNSPlacing
29th Apr 20167:00 amRNSNEW PUBLICATIONS UTILISING PARSORTIX
19th Apr 201612:43 pmRNSEdison issues research update on Angle
18th Apr 20167:00 amRNSParsortix potential in metastatic breast cancer
21st Mar 201612:12 pmRNSEdison issues research update on Angle
21st Mar 20167:00 amRNSParsortix potential for prostate cancer detection
9th Mar 20167:00 amRNSEuropean patent grant for Parsortix
28th Jan 20167:00 amRNSInterim Results
27th Jan 201610:42 amRNSNotice of Interim Results
25th Jan 20167:00 amRNSUKE publishes evaluation of Parsortix
22nd Dec 20157:00 amRNSCompletion of Geomerics Transaction
15th Dec 20157:00 amRNSParsortix first commercial sales
10th Dec 20157:00 amRNSChange of FTSE Industry Classification Benchmark
30th Nov 20155:56 pmRNSHolding(s) in Company
17th Nov 20157:00 amRNSLung Cancer Research Publication

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.